World's Best Scientists 2026 revealed!
Francisco J. Esteva

Francisco J. Esteva

D-Index & Metrics

Medicine

D-Index
89
Citations
34802
World Ranking
12543
National Ranking
6420

Overview

Francisco J. Esteva is affiliated with New York University in the United States. Their research primarily spans the fields of Medicine and Biochemistry, Genetics and Molecular Biology, with a focus on Oncology, Pulmonary and Respiratory Medicine, Cancer Research, Radiology, Nuclear Medicine and Imaging, and Molecular Biology.

The main topics of their research include:

  • HER2/EGFR in Cancer Research
  • Advanced Breast Cancer Therapies
  • Breast Cancer Treatment Studies
  • Monoclonal and Polyclonal Antibodies Research
  • Cancer Treatment and Pharmacology
  • Radiomics and Machine Learning in Medical Imaging
  • CAR-T cell therapy research

Esteva has contributed extensively to several publication venues, with multiple papers featured in Clinical Cancer Research, and additional publications in The Lancet Oncology, British Journal of Cancer, Cancers, and The Breast.

Notable recent papers authored or co-authored by Esteva include:

  • Trastuzumab emtansine plus atezolizumab versus trastuzumab emtansine plus placebo in previously treated, HER2-positive advanced breast cancer (KATE2): a phase 2, multicentre, randomised, double-blind trial, 2020, The Lancet Oncology
  • Safety and impact of dose reductions on efficacy in the randomised MONALEESA-2, -3 and -7 trials in hormone receptor-positive, HER2-negative advanced breast cancer, 2021, British Journal of Cancer
  • Ribociclib plus fulvestrant for advanced breast cancer: Health-related quality-of-life analyses from the MONALEESA-3 study, 2020, The Breast
  • LncRNA RP11-19E11 is an E2F1 target required for proliferation and survival of basal breast cancer, 2020, npj Breast Cancer
  • Next-Generation HER2-Targeted Antibody-Drug Conjugates in Breast Cancer, 2024, Cancers

Frequent co-authors in Esteva's collaborative research include Freya Schnabel, Seock-Ah Im, Arlene Chan, Aditya Bardia, and Patrick Neven, each contributing to multiple joint publications.

Best Publications

  • PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients

    Yoichi Nagata;Keng Hsueh Lan;Xiaoyan Zhou;Ming Tan

  • Mechanisms of Disease: understanding resistance to HER2-targeted therapy in human breast cancer

    Rita Nahta;Dihua Yu;Mien Chie Hung;Gabriel N. Hortobagyi

  • Insulin-like growth factor-I receptor/human epidermal growth factor receptor 2 heterodimerization contributes to trastuzumab resistance of breast cancer cells.

    Rita Nahta;Linda X.H. Yuan;Bing Zhang;Ryuji Kobayashi

  • Phase III Randomized Study of Ribociclib and Fulvestrant in Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer: MONALEESA-3

    Dennis J. Slamon;Patrick Neven;Stephen Chia;Peter A. Fasching

  • The HER-2-targeting antibodies trastuzumab and pertuzumab synergistically inhibit the survival of breast cancer cells.

    Rita Nahta;Mien Chie Hung;Francisco J. Esteva

  • Phase II Study of Weekly Docetaxel and Trastuzumab for Patients With HER-2–Overexpressing Metastatic Breast Cancer

    Francisco J. Esteva;Vicente Valero;Daniel Booser;Laura T. Guerra

  • Weekly Trastuzumab and Paclitaxel Therapy for Metastatic Breast Cancer With Analysis of Efficacy by HER2 Immunophenotype and Gene Amplification

    Andrew D. Seidman;Monica N. Fornier;Francisco J. Esteva;Lee Tan

  • Overall Survival with Ribociclib plus Fulvestrant in Advanced Breast Cancer.

    Dennis J. Slamon;Patrick Neven;Stephen Chia;Peter A. Fasching

  • Neoadjuvant Therapy with Paclitaxel followed by 5-Fluorouracil, Epirubicin, and Cyclophosphamide Chemotherapy and Concurrent Trastuzumab in Human Epidermal Growth Factor Receptor 2–Positive Operable Breast Cancer: An Update of the Initial Randomized Study Population and Data of Additional Patients Treated with the Same Regimen

    Aman U. Buzdar;Vicente Valero;Nuhad K. Ibrahim;Deborah Francis

  • Planning cancer control in Latin America and the Caribbean

    Paul E. Goss;Brittany L. Lee;Brittany L. Lee;Tanja Badovinac-Crnjevic;Kathrin Strasser-Weippl

  • Herceptin : mechanisms of action and resistance

    Rita Nahta;Francisco J. Esteva

  • Combating trastuzumab resistance by targeting SRC, a common node downstream of multiple resistance pathways

    Siyuan Zhang;Wen Chien Huang;Ping Li;Hua Guo

  • TBCRC 001: Randomized Phase II Study of Cetuximab in Combination With Carboplatin in Stage IV Triple-Negative Breast Cancer

    Lisa A. Carey;Hope S. Rugo;P. Kelly Marcom;Erica L. Mayer

  • National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines for Use of Tumor Markers in Testicular, Prostate, Colorectal, Breast, and Ovarian Cancers

    Catharine M. Sturgeon;Michael J. Duffy;Ulf Håkan Stenman;Hans Lilja

  • HER2 therapy: Molecular mechanisms of trastuzumab resistance

    Rita Nahta;Francisco J Esteva;Francisco J Esteva

  • Long-Term Cardiac Tolerability of Trastuzumab in Metastatic Breast Cancer: The M.D. Anderson Cancer Center Experience

    Valentina Guarneri;Daniel J. Lenihan;Vicente Valero;Jean Bernard Durand

  • Residual Risk of Breast Cancer Recurrence 5 Years After Adjuvant Therapy

    Abenaa M. Brewster;Gabriel N. Hortobagyi;Kristine R. Broglio;Shu Wan Kau

  • Systemic Therapy for Patients With Advanced Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline

    Sharon H. Giordano;Sarah Temin;Jeffrey J. Kirshner;Sarat Chandarlapaty

  • Trastuzumab: triumphs and tribulations.

    R Nahta;F J Esteva

  • PTEN activation contributes to tumor inhibition by trastuzumab and loss of PTEN predicts trastuzumab resistance in patients.

    Keng-Hsueh Lan;Yoichi Nagata;Xiaoyan Zhou;Francisco J. Esteva

Frequent Co-Authors

Gabriel N. Hortobagyi
Gabriel N. Hortobagyi The University of Texas MD Anderson Cancer Center
Lajos Pusztai
Lajos Pusztai Yale University
Vicente Valero
Vicente Valero The University of Texas MD Anderson Cancer Center
Massimo Cristofanilli
Massimo Cristofanilli Cornell University
Aysegul A. Sahin
Aysegul A. Sahin The University of Texas MD Anderson Cancer Center
Dihua Yu
Dihua Yu The University of Texas MD Anderson Cancer Center
Aman U. Buzdar
Aman U. Buzdar The University of Texas MD Anderson Cancer Center
Mien Chie Hung
Mien Chie Hung China Medical University
Naoto T. Ueno
Naoto T. Ueno University of Hawaiʻi Cancer Center
W. Fraser Symmans
W. Fraser Symmans The University of Texas MD Anderson Cancer Center

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

If you’re considering a career in medicine or healthcare, there are several online degree options and pathways to help you get started. For registered nurses seeking to enhance their qualifications, what is the cheapest rn to bsn program online is a common question. These programs allow RNs to earn their Bachelor of Science in Nursing (BSN) at a lower cost and with flexible schedules.

Those interested in advancing their nursing credentials without a prior nursing background can look into direct entry msn programs online. These fast-track options are designed for career changers who hold a non-nursing bachelor’s degree.

If admission competitiveness is a concern, applicants can explore direct admit nursing programs, which typically have more accessible entry requirements, making it easier to begin a nursing career.

For those seeking alternative healthcare roles, medical billing and coding offers promising opportunities. Many online programs are available, and it’s important to know can you get financial aid for medical billing and coding to help fund your education.

Best Scientists Citing Francisco J. Esteva

Trending Scientists

Recently Published Articles